Jump to content
Dr Sermorelin

A coastal-calm research digest of the sermorelin literature — GHRH(1-29), the growth-hormone axis, and the honest limits of the adult anti-aging evidence, read along one unhurried horizon line.

Original papers / follow a claim back to its study

Sermorelin references let you check who received treatment and what changed.

Sermorelin is the hormone-raising drug discussed in these papers. The list helps you find the research behind a claim. Each entry gives the authors, publication, year and a link leading to the paper.

Return to the measured resultsRead the older men's experiment

How the numbers beside Sermorelin claims lead to the papers

Sermorelin has been tested for raising growth hormone. This list helps you locate the paper behind a finding. Small numbers beside claims match the entries below. Each entry links to the paper.

The papers cover childhood growth and older men's hormone tests, drug timing and sleep. The adult thinking trial used tesamorelin. Reviews from 2023-2025 discuss growth hormone and aging. A review brings together findings from other studies. You can check which patients received which drug.

A review can't replace an adult health trial that hasn't happened.

  1. Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. (synthesis of GHRH(1-29) receptor mechanism and pharmacology) ↗
  2. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. ↗
  3. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. ↗
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. ↗
  5. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. ↗
  6. Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. ↗
  7. Yuen KCJ, et al. Growth Hormone Secretagogues as Potential Therapeutic Agents to Restore Growth Hormone Secretion in Older Subjects to Those Observed in Young Adults. J Gerontol A Biol Sci Med Sci. 2023. ↗
  8. Bartke A, et al. Growth hormone and aging: a clinical review. Front Aging. 2025. ↗
  9. Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. ↗
  10. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. NCT00257712. ↗
  11. Giovannini S, et al. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults. Mech Ageing Dev. 2008;129(10):593-601. ↗
  12. Thornton PL, et al. Chronic [D-Ala2]-growth hormone-releasing hormone administration attenuates age-related deficits in spatial memory. J Gerontol A Biol Sci Med Sci. 2000;55(2):B106-B112. ↗
  13. Steiger A, et al. The significance of sleep onset and slow wave sleep for nocturnal release of growth hormone (GH) and cortisol. Psychoneuroendocrinology. 1988;13(3):231-243. ↗
  14. Behrens S, et al. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. Eur J Endocrinol. 2004;151(5):561-566. ↗
  15. Guldner J, Schier T, Friess E, et al. Reduced efficacy of growth hormone-releasing hormone in modulating sleep endocrine activity in the elderly. Neurobiol Aging. 1997;18(5):491-495. ↗
  16. Munafo A, Nguyen TX, Papasouliotis O, et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. European journal of endocrinology. 2005;153:249-56. ↗
  17. Chen RG, Shen YN, Yei J, et al. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993;388:32-5; discussion 36. ↗
  18. Khorram O, Laughlin GA, Yen SS Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism. 1997;82:1472-9. ↗
  19. Lanes R, Carrillo E Long-term therapy with a single daily subcutaneous dose of growth hormone releasing hormone (1-29) in prepubertal growth hormone deficient children. Venezuelan Collaborative Study Group. The Journal of pediatric endocrinology. 1994;7:303-8. ↗
  20. Gelander L, Lindstedt G, Selstam G, et al. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion. Hormone research. 1989;31:213-20. ↗
  21. Tauber MT, Pienkowski C, Pigeon P, et al. Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993;388:28-30; discussion 31. ↗
  22. Coutinho LFD, DE Oliveira Neves LF, Camilo RP A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. 2026. ↗
  23. Mendias CL, Awan TM Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. ↗
  24. Villegas Meza AD, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS reviews. 2026;14. ↗
  25. Esposito S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. ↗
  26. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. ↗
  27. Ko FY, Chen WP, Lin CY Defective response of plasma growth hormone to growth hormone releasing factor in growth hormone deficient children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1992;33:243-50. ↗
  28. Tuilpakov AN, et al. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism. 1995;44:1199-204. ↗
  29. Yuen KC, Biller BM, Molitch ME, Cook DM. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab. 2009;94(8):2702-2707. ↗
  30. U.S. Food and Drug Administration Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Guidance for Industry). FDA Guidance for Industry. 2025. ↗